Skip to main content
. Author manuscript; available in PMC: 2011 Oct 9.
Published in final edited form as: Gastroenterology. 2009 Jun 12;137(3):856–864.e1. doi: 10.1053/j.gastro.2009.06.006

Figure 2.

Figure 2

Kaplan-Meier curve for each group (treatment by coma category) was used to show overall survival to 365 days. In separate analyses, patients in the NAC I–II group demonstrated significantly higher survival than either Placebo III–IV (p = 0.012) or NAC III–IV (p = 0.002). Number of patients with censored data prior to 365 days: 14 in NAC I–II, 5 in NAC III–IV, 12 in Placebo I–II, 7 in Placebo III–IV.